Skip to main content
TipRanks
Go Ultimate75% OFF

John Mendlein Insider Profile

11 Followers

John Mendlein, Director at Fate Therapeutics, holds 311.23K shares in Fate Therapeutics (Ticker: FATE), holds 615.38K shares in aTyr Pharma (Ticker: ATYR), holds ― shares in Editas Medicine (Ticker: EDIT).

John Mendlein's Trading History

FATE
Fate Therapeutics
Jan 20, 2023DirectorUninformative Buy38.99K$398.38K
ATYR
aTyr Pharma
Dec 26, 2018DirectorInformative Buy102.40K$3.76M
OMGAQ
Omega Therapeutics
――――
EDIT
Editas Medicine
―Director――

You May Also Like

John Mendlein insider profile FAQ

What is the percentage of profitable transactions made by John Mendlein?
The percentage of profitable transactions made by John Mendlein is 33%.
What is the average return per transaction made by John Mendlein?
The average return per transaction made by John Mendlein is 11.10%.
What stocks does John Mendlein hold?
John Mendlein holds: FATE, ATYR, EDIT, OMGAQ stocks.
What was John Mendlein’s latest transaction?
John Mendlein’s latest transaction was an Uninformative Buy of $38.99K.
What was John Mendlein's most profitable transaction?
John Mendlein’s most profitable transaction was an Informative Sell of FATE stock on June 6, 2022. The return on the trade was 75.40%.
What is John Mendlein's role in Fate Therapeutics?
John Mendlein's role in Fate Therapeutics is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.

TipRanks measures corporate insiders by the stock transactions they report to the SEC. See how TipRanks ranks experts and calculates performance.